Musi wa24 Nyamavhuvhu, 2022, US Food and Drug Administration (FDA) yakabvumidza ibrutinib yekurapa varwere vane makore anopfuura gore rimwe chete vane chirwere chisingaperi chegraft-versus-host (cGVHD) vari kugamuchira mushure mekukundikana kwe1- kana multi-line systemic therapy. Chiratidzo chakabvumidzwa chinonyanya kuitirwa varwere vevana, nehuwandu hwemhinduro hwe60% pavhiki rechi25, uye mishonga iyi inosanganisira makapisiri, mapiritsi uye mishonga inomiswa nemuromo.
Ibrutinib, mushonga unodzivirira BTK wakagadzirwa pamwe chete nePharmacyclics/Johnson & Johnson, mushonga unodzivirira masero eropa wakambobvumidzwa kurapa chronic lymphocytic leukemia pamwe ne cell lymphoma nezvimwe zvirwere.
Suntech inotarisa pakugadzira nekugadzira mishonga yepakati uye maAPI uchishandisa tekinoroji yegirini. Parizvino, kambani yedu yakagadzira zvigadzirwa zvitatu zvepakati zveibrutinib zvinosanganisira C AS: 143900-44-1, C AS: 330792-70-6, C AS: 330786-24-8, zvese izvi zvakatengeswa mumafekitori eGMP. Pakati pazvo, chikamu chepakati cheC AS: 143900-44-1 chinogadzirwa netekinoroji yemakemikari-enzyme, ine zvakanakira zvekuchengetedza nharaunda yakasvibirira, mutengo wakaderera uye mhando yepamusoro. Tinokugamuchirai kuti mubvunze nekushandira pamwe!
Nguva yekutumira: Mbudzi-04-2022